PubRank

Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome

Clinical Trial ID NCT05221021

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT05221021

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003 9.92
2 Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015 4.57
3 Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002 2.66
4 Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol 2013 2.01
5 Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2009 1.94
6 Prevalence and effect on health-related quality of life of overactive bladder in older americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc 2011 1.89
7 Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol 2013 1.83
8 Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013 1.68
9 Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology 2004 1.67
10 Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause 2011 1.50
11 Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm 2014 1.36
12 Determining the importance of change in the overactive bladder questionnaire. J Urol 2006 1.19
13 Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol 2014 1.17
14 Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder. Clin Ther 2013 1.17
15 Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2012 1.11
16 An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF. Neurourol Urodyn 2014 1.00
17 Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome. Eur Urol 2015 0.97
18 Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet 2003 0.95
19 A randomized comparative study of the effects of oral and topical estrogen therapy on the lower urinary tract of hysterectomized postmenopausal women. Fertil Steril 2006 0.90
20 Vaginal oestradiol for the treatment of lower urinary tract symptoms in postmenopausal women--a double-blind placebo-controlled study. J Obstet Gynaecol 2001 0.85
21 Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. BJOG 2000 0.82
22 The Burden of Overactive Bladder on US Public Health. Curr Bladder Dysfunct Rep 2016 0.81
23 Urgency urinary incontinence and the interoceptive network: a functional magnetic resonance imaging study. Am J Obstet Gynecol 2016 0.78
24 The role of mirabegron in overactive bladder: a systematic review and meta-analysis. Urol Int 2014 0.77
25 Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy Treatment. Female Pelvic Med Reconstr Surg 2016 0.75
Next 100